UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Explore practical signs you should modify your spending plan and a straightforward approach to refreshing priorities for better outcomes.
21,708 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Ferrari's latest results underscore its asset-like status, delivering strong cash flow while preparing for an electri...
Bitcoin climbs on geopolitical optimism, with traders betting on a swift de-escalation. The market sees a surge in se...
Spring 2026 opens with a housing market shaped by jobs data, energy prices, and mortgage-rate swings. This article ou...
In Washington, governors from both parties pressed for a sweeping review of the nation’s workforce policy amid AI-dri...
Sonic Automotive and Penske Automotive Group post mixed Q4 results as tariff fears shape growth paths. EchoPark expan...
Policy makers weigh oil futures as a tool to cool prices amid Iran-related tensions. Burgum signals discussions occur...
An accidental mass email turns a shy campus newcomer into a social-media sensation and a thriving pet-sitting busines...
Stellus Capital Investment Corp remains a high-yield option in private credit, yet recent earnings misses and a divid...
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Lululemon beat on Q4 revenue and EPS, but 2026 guidance signals slower growth and ongoing governance questions. Inves...
Lawyers for Luigi Mangione ask a federal judge to delay the federal murder trial and move the state case to September...